About jsexton

This author has not yet filled in any details.
So far jsexton has created 4 blog entries.

High Content Screening – Human Muscle Stem Cells

By | 2018-06-26T17:08:38-04:00 June 26th, 2018|

High-Content Screening of Human Primary Muscle Satellite Cells for New Therapies for Muscular Atrophy/Dystrophy Results are encouraging A high-content/high-throughput platform was developed and utilized for robust phenotypic evaluation of human primary satellite cells in vitro for the discovery of chemical probes that may improve muscle recovery. A 1600 compound pilot screen [...]

Insulin FP Biosensor

By | 2018-06-26T16:50:15-04:00 June 26th, 2018|

Development of a Cell-Based Fluorescence Polarization Biosensor Using Preproinsulin to Identify Compounds That Alter Insulin Granule Dynamics A new tool for studying insulin packaging and dynamics In this paper, we described a fluorescent insulin reporter system (preproinsulin-mCherry, PPI-mCherry) that tracks live-cell insulin dynamics and secretion in pancreatic beta cells with utility [...]

Niclosamide and Analogs Improve Fatty Liver Disease

By | 2018-06-26T16:34:38-04:00 June 26th, 2018|

N-substituted Phenylbenzamides of the Niclosamide chemotype attenuate obesity related changes in high fat diet fed mice Results are encouraging In this manuscript, submitted to PLOS One, we describe that Niclosamide, an FDA-approved anthelmintic drug, and its phenylbenzamide analogs have efficacy in murine models of diet induced obesity characterized by attenuation of the prominent [...]

Non Alcoholic Fatty Liver Disease

By | 2018-06-26T15:52:48-04:00 June 26th, 2018|

NAFLD, an epidemic and a health disparity   In association with the blanket term “metabolic syndrome” (which can be defined by increased insulin resistance, diabetes, obesity, increased blood pressure, high blood sugar, abnormal cholesterol or triglyceride levels, etc.) is non-alcoholic fatty liver disease (NAFLD), a burgeoning chronic hepatic disorder affecting ~25% of the world’s [...]